Recombinant Human IL-13 R alpha 2 Fc Chimera (CHO), CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Interleukin‑13 Receptor alpha 2 (IL‑13 R alpha 2), also known as IL‑13 binding protein, and CD213a2, is a widely expressed 55 kDa cytokine receptor that plays an important role in the Th2‑polarized immune responses characteristic of a variety of pathologies, including parasitic infections and allergic asthma (1, 2). Mature human IL‑13 R alpha 2 consists of a 317 amino acid (aa) extracellular domain with three fibronectin type‑III domains, a WSxWS motif, a 20 aa transmembrane segment, and a 17 aa cytoplasmic domain (3). Within the ECD, human IL‑13 R alpha 2 shares 64% and 62% aa sequence identity with mouse and rat IL‑13 R alpha 2, respectively. In both mouse and human, a 40 kDa‑50 kDa soluble form of IL‑13 R alpha 2 can be generated by MMP‑8 mediated shedding in vitro (4).  Although this is assumed to occur in vivo in mouse, there is no evidence that shedding occurs in human (5‑7).  In mouse, alternative splicing also leads to sIL‑13 R alpha 2, but again, this phenomenon apparently does not occur in human (6‑7).  Thus, the biological effects of human IL‑13 R alpha 2 would appear to be mediated exclusively by membrane IL‑13 R alpha 2 (7). The biological effects of IL‑13 and IL‑4 are closely related in part due to a shared receptor system. IL‑13 binds to IL‑13 R alpha 1 which then forms a signaling complex with IL‑4 R alpha (8, 9). IL‑13 R alpha 2 functions as a decoy receptor by binding and internalizing IL‑13 and preventing it from signaling through the IL‑13 R alpha 1/IL‑4 R alpha complex (3, 10). IL‑13 R alpha 2 can also block IL‑4 induced responses by inhibiting IL‑4 bound IL‑13 R alpha 1/IL‑4 R alpha receptor complexes even though it does not itself bind IL‑4 (11, 12). Aside from its decoy function, IL‑13‑activated IL‑13 R alpha 2 directly promotes the development of tissue fibrosis by inducing the transcription of TGF‑ beta (13). Presumably, any human soluble IL‑13 R alpha 2, if it exists, will retain its ligand binding capability and attenuate responses to IL‑13 but not to IL‑4 (11, 14). The up‑regulation of transmembrane during Th2‑biased immune responses limits the extent of those responses (15‑17).

We have publications tested in 1 confirmed species: Human.

We have publications tested in 4 applications: Bioassay, CAR-T (Bioassay), Cell Culture, ELISA Capture.

Showing Publications 1 - 6 of 6.

Publications using 7147-IR	Applications	Species
Pawlowski, KD;Duffy, JT;Tiwari, A;Zannikou, M;Balyasnikova, IV; Bi-Specific Killer Cell Engager Enhances NK Cell Activity against Interleukin-13 Receptor Alpha-2 Positive Gliomas Cells 2023-06-25 [PMID: 37443750] (ELISA Capture, Human)	ELISA Capture	Human
LA Stern, S Gholamin, I Moraga, X Yang, S Saravanaku, JR Cohen, R Starr, B Aguilar, V Salvary, JC Hibbard, A Kalbasi, JK Shepphird, J O'Hearn, KC Garcia, CE Brown Engineered IL13 variants direct specificity of IL13Ralpha2-targeted CAR T cell therapy Proceedings of the National Academy of Sciences of the United States of America, 2022-08-08;119(33):e2112006119. 2022-08-08 [PMID: 35939683] (Cell Culture, Human)	Cell Culture	Human
CE Brown, B Aguilar, R Starr, X Yang, WC Chang, L Weng, B Chang, A Sarkissian, A Brito, JF Sanchez, JR Ostberg, M D'Apuzzo, B Badie, ME Barish, SJ Forman Optimization of IL13R?2-Targeted Chimeric Antigen Receptor T Cells for Improved Anti-tumor Efficacy against Glioblastoma Mol. Ther., 2017-10-05;26(1):31-44. 2017-10-05 [PMID: 29103912] (Cell Culture, Human)	Cell Culture	Human
Bielamowicz K, Fousek K, Byrd T, Samaha H, Mukherjee M, Aware N, Wu M, Orange J, Sumazin P, Man T, Joseph S, Hegde M, Ahmed N Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma. Neuro Oncol, 2018-03-27;20(4):506-518. 2018-03-27 [PMID: 29016929] (CAR-T (Bioassay), Human)	CAR-T (Bioassay)	Human
Mahadev V, Starr R, Wright S, Martinez C, Jensen M, Barish M, Forman S, Brown C Cytokine induction of VCAM-1 but not IL13Ralpha2 on glioma cells: a tale of two antibodies. PLoS ONE, 2014-05-02;9(5):e95123. 2014-05-02 [PMID: 24787244] (Bioassay, Human)	Bioassay	Human
Hegde M, Corder A, Chow K, Mukherjee M, Ashoori A, Kew Y, Zhang Y, Baskin D, Merchant F, Brawley V, Byrd T, Krebs S, Wu M, Liu H, Heslop H, Gottschalk S, Yvon E, Ahmed N Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther, 2013-08-13;21(11):2087-101. 2013-08-13 [PMID: 23939024] (CAR-T (Bioassay), Human)	CAR-T (Bioassay)	Human

Array 7147-IR

• IL-13R alpha 2 Antibodies
• IL-13R alpha 2 ELISA Kits
• IL-13R alpha 2 Lysate
• IL-13R alpha 2 Proteins
• IL-13R alpha 2 Proteins and Enzymes
• IL-13R alpha 2 ELISAs